Annual Relapse Rates (ARR) in Patients with Spinal Progressive Multiple Sclerosis Treated with MD1003 (High-Dose Pharmaceutical Biotin)

被引：0
|
作者：
Morteau, Olivier [1 ]
Lasser, Robert [1 ]
Sedel, Frederic [1 ]
Brion, Guillaume [1 ]
Tourbah, Ayman [2 ]
Simon, Olivier [1 ]
机构：
[1] MedDay Pharmaceut, Paris, France
[2] Hop Maison Blanche, Reims, France
来源：
MULTIPLE SCLEROSIS JOURNAL | 2018年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P045
引用
收藏
页码：31 / 31
页数：1
相关论文
共 50 条
  • [1] Biomarkers of treatment response in patients with progressive multiple sclerosis treated with high-dose pharmaceutical-grade biotin (MD1003)
    Collongues, Nicolas
    Kuhle, Jens
    Tsagkas, Charidimos
    Lamy, Julien
    Meyer, Nicolas
    Barro, Christian
    Parmar, Katrin
    Amann, Michael
    Wuerfel, Jens
    Kappos, Ludwig
    Moreau, Thibault
    Seze, Jerome
    [J]. BRAIN AND BEHAVIOR, 2021, 11 (02):
  • [2] Effect of MD1003 (High-Dose Pharmaceutical Biotin) in Spinal Progressive Multiple Sclerosis (MS-SPI): Subgroup Analyses
    Laplaud, David-Axel
    Gout, Olivier
    Clavelou, Pierre
    Pelletier, Jean
    Simon, Olivier
    Sedel, Frederic
    Tourbah, Ayman
    Lasser, Robert
    Morteau, Olivier
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 33 - 33
  • [3] Pharmacokinetics and pharmacodynamics of MD1003 (high-dose biotin) in the treatment of progressive multiple sclerosis
    Saint Paul, Laure Peyro
    Debruyne, Daniele
    Bernard, Delphine
    Mock, Donald M.
    Defer, Gilles L.
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (03) : 327 - 344
  • [4] Effect of MD1003 (High-Dose Biotin) in spinal progressive multiple sclerosis (MS-SPI): subgroup analyses
    Laplaud, D. -A.
    Gout, O.
    Clavelou, P.
    Pelletier, J.
    Sedel, F.
    Tourbah, A.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 402 - 403
  • [5] Effect of MD1003 (High-Dose Pharmaceutical Biotin) in Spinal Progressive Multiple Sclerosis (MS-SPI): EDSS Sub-Scores
    Papeix, Caroline
    Lebrun-Frenay, Christine
    Defer, Gilles
    Laubage, Pierre
    Ruiz, Marta
    Simon, Olivier
    Sedel, Frederic
    Tourbah, Ayman
    Lasser, Robert
    Morteau, Olivier
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 34 - 34
  • [6] MD1003 (High-Dose Pharmaceutical Biotin) for the Treatment of Progressive Multiple Sclerosis: Baseline Data and Results from an Early Access Program
    Brassat, David
    Hautecoeur, Patrick
    Durand-Dubief, Francoise
    Castelnovo, Giovanni
    Derache, Nathalie
    Bourre, Bertrand
    Donze, Cecile
    Ouallet, Jean-Christophe
    Collongues, Nicolas
    Simon, Olivier
    Brion, Guillaume
    Sedel, Frederic
    Vermersch, Patrick
    Lasser, Robert
    Morteau, Olivier
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 31 - 32
  • [7] High-dose pharmaceutical grade biotin (MD1003) in amyotrophic lateral sclerosis: A pilot study
    Juntas-Morales, Raul
    Pageot, Nicolas
    Bendarraz, Abdelkarim
    Alphandery, Sebastien
    Sedel, Frederic
    Seigle, Stephanie
    Camu, William
    [J]. ECLINICALMEDICINE, 2020, 19
  • [8] Effect of MD1003 (High-Dose Biotin) in spinal progressive multiple sclerosis (MS-SPI): EDSS sub-scores
    Papeix, C.
    Lebrun-Frenay, C.
    Defer, G.
    Labauge, P.
    Ruiz, M.
    Simon, O.
    Tourbah, A.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 938 - 939
  • [9] Long term effect of MD1003 (high dose pharmaceutical grade biotin) in a cohort of patients with progressive non-active multiple sclerosis
    Donze, C.
    Guyot, M. A.
    Kwiatkowski, A.
    Hautecoeur, P.
    Massot, C.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 385 - 385
  • [10] Immunomodulation associated with clinical and MRI worsening in patients with progressive MS treated with MD1003 (high dose pharmaceutical grade biotin)
    Pignolet, B.
    Ciron, J.
    Bucciarelli, F.
    Scandella, L.
    Biotti, D.
    Lerebours, F.
    Dorcet, G.
    Rabadeux, C.
    Freitas, N.
    Bonneville, F.
    Brassat, D.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 467 - 468
12345